내시경 치료 기기 시장 : 제품 유형별, 기술별, 용도별, 최종사용자별, 유통 채널별 - 세계 예측(2026-2032년)

The Endotherapy Devices Market was valued at USD 5.80 billion in 2025 and is projected to grow to USD 6.20 billion in 2026, with a CAGR of 7.96%, reaching USD 9.92 billion by 2032.

Comprehensive introduction to endotherapy devices highlighting clinical evolution, technology convergence, safety priorities, and commercial drivers reshaping adoption

Endotherapy devices have entered a phase of rapid clinical and commercial maturation driven by convergent advances in optics, materials science, and procedural practice. Clinicians increasingly demand tools that deliver superior visualization while reducing procedural risk and throughput time, and manufacturers are responding with innovations spanning single-use platforms, enhanced imaging modalities, and modular service offerings. As a result, procurement teams and clinical leaders are reconsidering long-standing assumptions around device lifecycle, cost of ownership, and infection control.

Moreover, the clinical imperative to improve patient outcomes and procedural efficiency is aligning with broader systemic priorities, including supply chain reliability and regulatory scrutiny. This alignment has elevated device sterility, ease of reprocessing, and interoperability with digital systems as core selection criteria. Consequently, companies that can demonstrate robust clinical evidence, streamlined logistics, and predictable total cost profiles are increasingly favored by hospital systems and ambulatory centers.

Taken together, these forces have reshaped competitive dynamics and created new entry points for technology providers. Strategic clarity around clinical value propositions, evidence generation, and channel engagement will determine which firms convert innovation into widespread adoption and sustained commercial success.

Analysis of transformative shifts driving the endotherapy landscape including single-use adoption, imaging advances, AI enablement, and regulatory inflection points

The landscape of endotherapy devices is changing in fundamental ways that extend beyond incremental product upgrades. Single-use flexible and rigid devices are transforming procurement and infection control paradigms, reducing reprocessing burdens and shifting service economics. At the same time, imaging innovations such as high-definition and narrow band imaging have raised the clinical bar for lesion detection and therapeutic precision, prompting clinicians to prefer devices that integrate advanced optics and improved illumination.

Concurrently, digital enablement through image analytics and early-stage artificial intelligence is beginning to influence workflow optimization and diagnostic consistency. Robotics and enhanced endoscope maneuverability are expanding procedural capabilities, reducing operator fatigue and broadening the range of minimally invasive interventions. These technological shifts are complemented by operational adjustments: health systems are consolidating supplier relationships, emphasizing service contracts and bundled procurement, while regulatory agencies are tightening guidance around device reprocessing and environmental safety.

As a result, companies must pivot from product-centric roadmaps to solutions that combine clinical evidence, digital integration, and lifecycle services. Those that successfully align innovation investments with evolving provider needs, reimbursement realities, and regulatory expectations will secure advantaged positions in an increasingly outcomes-driven market.

Assessment of the cumulative impact of United States tariff measures introduced in 2025 on supply chains, procurement decisions, and product design incentives

The cumulative effects of tariff measures introduced in 2025 have created immediate and second-order consequences across the endotherapy device ecosystem. In the near term, increased import duties have raised landed costs for devices and key components, prompting procurement teams to re-evaluate supplier portfolios and consider alternative sourcing strategies. This pressure has accelerated interest in local manufacturing and nearshoring initiatives, as stakeholders prioritize supply chain resilience and predictable lead times.

Over time, these trade measures have influenced product-level decisions. Manufacturers with geographically diversified production footprints have been better positioned to absorb cost pressure and maintain contractual pricing stability, whereas firms reliant on single-region supply have had to either renegotiate commercial terms or pass increased costs downstream. For healthcare providers, the tariff environment has heightened scrutiny of total ownership costs, sterilization expenditures, and the comparative economics of reusable versus single-use devices.

Furthermore, tariffs have catalyzed strategic responses beyond pricing. Some companies have intensified partnerships with distributors and local assemblers to mitigate duties, while others have increased investment in product designs that rely less on tariff-exposed components. In parallel, procurement organizations have leveraged longer-term agreements and volume commitments to secure price certainty. Ultimately, the tariff-driven adjustments are accelerating structural shifts that were already underway: a move toward supply chain diversification, heightened emphasis on domestic capabilities, and a renewed focus on demonstrable clinical and economic value.

Strategic segmentation insights explaining how product, application, end user, channel, and imaging technology distinctions influence clinical priorities and commercialization strategies

Insight into segmentation reveals how product, application, end user, distribution, and technology distinctions shape strategic priorities and innovation pathways. Based on product type the landscape includes capsule endoscopes alongside both flexible endoscopes and rigid endoscopes, with flexible models further differentiated into reusable flexible endoscopes and single-use flexible endoscopes while rigid endoscopes are examined across reusable rigid endoscopes and single-use rigid endoscopes. This product-level granularity influences decisions around sterilization protocols, device ergonomics, and service models, and it determines which firms invest in disposability versus durable instrumentation.

Based on application the field spans arthroscopy, gastrointestinal endoscopy, pulmonary endoscopy, and urological endoscopy, with gastrointestinal procedures further divided into lower and upper gastrointestinal endoscopy and urological procedures separated into cystoscopy and ureteroscopy. Each application segment imposes distinct clinical requirements, imaging preferences, and accessory ecosystems, thereby guiding product feature priorities and clinical evidence needs. Based on end user healthcare delivery settings range from ambulatory surgical centers to clinics and hospitals, and these settings exhibit different purchasing cycles, sterilization resources, and procedural volumes that affect device selection and service expectations.

Based on distribution channel procurement occurs through direct tender arrangements as well as distributor wholesaler networks, and channel choice impacts commercial models, service delivery, and aftermarket support. Based on technology offerings encompass 3D imaging, high definition imaging, and narrow band imaging, and these technological pathways drive differentiation in lesion detection capability, therapeutic accuracy, and integration with image analytics. Understanding the interplay among these segmentation axes is essential for tailoring product portfolios, targeting clinical partnerships, and aligning commercialization strategies with end-user workflows.

Key regional insights into how the Americas, Europe Middle East & Africa, and Asia-Pacific each shape adoption dynamics, regulatory interactions, and manufacturing strategies

Regional dynamics continue to dictate adoption patterns, regulatory interactions, and manufacturing strategies across the global endotherapy environment. In the Americas procurement sophistication and a strong emphasis on infection control have propelled interest in single-use devices and advanced imaging tools, while regional innovation hubs support clinical trials and post-market evidence generation. Meanwhile, reimbursement frameworks and hospital consolidation trends influence how quickly new technologies can be integrated into procedural pathways, with large health systems serving as early adopters for technologies that demonstrably improve outcomes.

In Europe, Middle East & Africa regulatory harmonization efforts and diverse payer landscapes create a mosaic of adoption timelines and cost sensitivities. In several European markets, centralized procurement and robust reprocessing infrastructures continue to support reusable device models, yet infection control imperatives and lifecycle cost scrutiny are increasing demand for single-use alternatives in specific clinical settings. Emerging markets within this region present growth opportunities linked to expanding procedural access and investments in diagnostic capacity, though pricing and infrastructure constraints require tailored go-to-market approaches.

Across Asia-Pacific a combination of rapid procedural uptake, growing domestic manufacturing capabilities, and policy emphasis on healthcare modernization has encouraged both innovation and competitive pressure. Local manufacturers and global firms operating in the region must navigate a range of regulatory regimes, local content expectations, and clinical training needs. Taken together, geographic distinctions underscore the necessity of region-specific commercialization playbooks that account for regulatory nuance, procurement mechanics, and clinical adoption drivers.

Key company-level insights into how incumbents and new entrants use portfolio expansion, partnerships, and evidence generation to secure clinical adoption and commercial advantage

Competitive dynamics among leading companies are being redefined by the interplay of innovation, service economics, and strategic partnerships. Established device manufacturers are expanding their portfolios to include single-use options, enhanced imaging capabilities, and bundled service agreements to lock in hospital relationships and create predictable revenue streams. At the same time, new entrants specializing in disposables, optics, or digital analytics are leveraging focused R&D and nimble commercialization to capture niche use cases and clinical champions.

Collaboration between device makers and clinical research organizations is becoming more strategic, with joint programs designed to produce robust evidence that supports adoption in procedural specialties. Similarly, alliances with distributors and local service providers are essential for scaling after-sales support and reprocessing alternatives in regions where centralized sterilization remains prevalent. Mergers, acquisitions, and licensing deals are playing a role in consolidating technology stacks and accelerating time-to-market for advanced imaging and single-use platforms.

Ultimately, companies that align R&D investments with clear clinical use cases, invest in training and service delivery, and create flexible commercial models will be positioned to win. Strategic clarity around aftermarket services, consumable economics, and digital integration will determine which players sustain profitable growth and long-term provider partnerships.

Actionable recommendations for industry leaders to enhance resilience, accelerate clinical adoption, and align product and commercial strategies with evolving provider priorities

Industry leaders should pursue a coordinated set of actions that balance near-term resilience with long-term competitiveness. First, diversify manufacturing and sourcing to reduce tariff exposure and supply volatility while also evaluating nearshoring or regional assembly options that improve lead times. In parallel, prioritize product designs that reduce reliance on tariff-sensitive components and that simplify sterilization to meet heightened infection control expectations.

Second, accelerate development of single-use offerings alongside durable platforms and create clear clinical and economic narratives that help providers assess total ownership and safety trade-offs. Evidence generation must be proactive: invest in pragmatic clinical studies and real-world data initiatives that demonstrate improvements in procedural outcomes, throughput, and cost-efficiency. Third, strengthen channel and service models by forming deeper partnerships with distributors and health systems, offering bundled maintenance or consumable agreements that create predictable revenue and improve customer retention.

Finally, engage early with regulators and payers to clarify clinical benefit thresholds and reimbursement pathways, and embed digital capabilities such as enhanced imaging interoperability and analytics to differentiate products. By integrating these strategic moves, organizations can transform short-term challenges into durable competitive advantages and align innovation with provider and patient needs.

Rigorous mixed-methods research methodology combining primary clinician and procurement inputs with secondary evidence synthesis and expert validation for defensible insights

The research underpinning this executive summary employs a mixed-methods approach that integrates primary qualitative interviews, secondary literature synthesis, and structured triangulation to ensure robust conclusions. Primary inputs included consultations with clinical specialists, procurement leaders, and device engineers to capture frontline perspectives on usability, reprocessing burdens, and clinical evidence requirements. Secondary analysis drew on regulatory guidance documents, clinical trial registries, and peer-reviewed literature to validate technological claims and map regulatory trends.

Data triangulation was applied across multiple sources to reconcile differing perspectives and to highlight consensus themes, such as the growing importance of single-use platforms and advanced imaging. Expert panels were convened to test preliminary findings and to identify risk factors related to supply chain disruption, tariff exposure, and adoption barriers. Where applicable, device lifecycle and procurement process frameworks were used to standardize comparisons across product types and end-user settings.

Limitations of the methodology include variability in publicly available clinical evidence across device categories and the dynamic nature of trade and regulatory environments. To mitigate these constraints, the study emphasizes qualitative validation, cross-regional comparisons, and scenario-based implications rather than quantitative forecasts, thereby providing actionable and defensible insights for strategic decision-making.

Concise conclusion emphasizing the need for evidence-driven innovation, supply chain resilience, and integrated commercial strategies to realize long-term growth

In conclusion, the endotherapy device landscape is being reshaped by a confluence of clinical, technological, and commercial forces that demand strategic agility. Advances in imaging and device design are enhancing diagnostic precision and therapeutic capability, while single-use platforms and evolving sterilization imperatives are altering procurement and service models. Trade dynamics and tariff measures have accelerated supply chain diversification and prompted renewed attention to regional manufacturing strategies.

Providers and manufacturers alike must prioritize evidence generation, supply chain resilience, and differentiated service models to thrive in this environment. By aligning product development with demonstrable clinical value and by engaging proactively with payers and regulators, organizations can navigate current headwinds and capitalize on emerging opportunities. The path forward requires integrated strategies that combine technological innovation, commercial flexibility, and deep clinical partnership to ensure that devices deliver measurable improvements in patient care and operational performance.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endotherapy Devices Market, by Product Type

• 8.1. Capsule Endoscopes
• 8.2. Flexible Endoscopes
• 8.3. Rigid Endoscopes

9. Endotherapy Devices Market, by Technology

• 9.1. 3D Imaging
• 9.2. High Definition Imaging
• 9.3. Narrow Band Imaging

10. Endotherapy Devices Market, by Application

• 10.1. Arthroscopy
• 10.2. Gastrointestinal Endoscopy
  • 10.2.1. Lower Gastrointestinal Endoscopy
  • 10.2.2. Upper Gastrointestinal Endoscopy
• 10.3. Pulmonary Endoscopy
• 10.4. Urological Endoscopy
  • 10.4.1. Cystoscopy
  • 10.4.2. Ureteroscopy

11. Endotherapy Devices Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Clinics
• 11.3. Hospitals

12. Endotherapy Devices Market, by Distribution Channel

• 12.1. Direct Tender
• 12.2. Distributor Wholesaler

13. Endotherapy Devices Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Endotherapy Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Endotherapy Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Endotherapy Devices Market

17. China Endotherapy Devices Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Boston Scientific Corporation
• 18.6. CONMED Corporation
• 18.7. Cook Medical LLC
• 18.8. ERBE Elektromedizin GmbH
• 18.9. Fujifilm Holdings Corporation
• 18.10. Globus Medical, Inc.
• 18.11. Intuitive Surgical, Inc.
• 18.12. Johnson & Johnson
• 18.13. Karl Storz SE & Co. KG
• 18.14. Medtronic PLC
• 18.15. Olympus Corporation
• 18.16. Otsuka Holdings Co., Ltd.
• 18.17. Pentax Medical Company, Ltd.
• 18.18. Renishaw PLC